7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine CAS 937046-98-5 Remdesivir Intermediate COVID-19
Manufacturer Commercial Supple Remdesivir et intermedia cum High Quality
Remdesivir CAS 1809249-37-3
2-Ethyl-1-butanol CAS 97-95-0
Trimethylsilyl Cyanide CAS 7677-24-9
4-Nitrophenol CAS 100-02-7
2-Ethylbutyl((S)-(perfluorophenoxys)(phosphoryl)-L-alaninatum CAS 1911578-98-7
N-[(S)-(4-nitrophenoxy) phenoxyphosphinyl]-L-Alanine 2-ethylbutyl ester CAS 1354823-36-1
(S)-2-Ethylbutyl 2-Aminopropanoate Hydrochloride CAS 946511-97-3
Remdesivir metabolitae (GS-441524) CAS 1191237-69-0
Remdesivir N-2 Intermedia CAS 1191237-80-5
2,3,5-Tri-O-benzyl-D-ribonolactone CAS 55094-52-5
7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine CAS 937046-98-5
Pyrrolo[1,2-F][1,2,4]Triazin-4-Amine CAS 159326-68-8
4-Amino-7-iodopyrrolo[2,1-f][1,2,4]triazine CAS 1770840-43-1
Nomen chemicum | 7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine |
Synonyma | 4-Amino-7-bromopyrrolo[2,1-f][1,2,4]triazine;Remdesivir Impuritas 2 |
CAS Number | 937046-98-5 |
CATTUS Number | RF-PI305 |
Stock Status | In Stock, Productio Ascendite usque ad Centum chiliogrammata |
Formulae hypotheticae | C6H5BrN4 |
M. Pondus | 213.04 |
Brand | Ruifu Chemical |
Item | Specifications |
Aspectus | Lumen Yellow Pulvis |
Infrared Imaginis | Conformat ut Structure |
NMR | Conformat ut Structure |
Puritas | ≥97.0% |
Damnum in Siccatio | ≤1.0 |
una immunditia | ≤1.0% |
Metalla gravis | ≤20ppm |
Test Standard | Enterprise Standard |
Consuetudinem | Intermedia Remdesiviri (CAS 1809249-37-3) |
sarcina: Utrem, aluminium foil, pera, cardboard tympanum, 25kg/Drum, vel secundum exigentiam emptoris.
Repono Condition:Repone in vasis signatis in loco frigido et sicco;Protege a lumine, humore et pestis infestatione.
7-Bromopyrrolo[2,1-f][1,2,4]triazin-4-amine (CAS 937046-98-5) est medius Remdesivir (CAS 1809249-37-3).Remdesivir est pharmacum antivirale cum actione coronavirus 2 syndrome respiratorii acuto contra acutum (SARS-CoV-2).Remdesivir (etiam notus ut Veklury vel GS-5734) est SARS-CoV-2 nucleotide analog RNA polymerasis inhibitor indicatus pro aegris adultis et pediatricibus (XII annis etatis et maioribus et saltem 40 kg) ad tractationem morborum coronavirorum MMXIX. (COVID-19) hospitalizationem postulantes.Remdesivir solum in nosocomio vel in adiunctis valetudinariis administrari debet idoneum curam acrem curare comparandum cum inpatienti hospitali cura.Remdesivir primum evolvit ut anti-virale contra virus Ebola, sed cum ostensum est onera viralium attenuata plurium RNA virus syncytialium respiratorii (RSV) et β-coronaviri sicut SARS-CoV, MERS-CoV, et causativum agentis COVID-XIX, SARS-CoV-II.